Table 1 Stage III CM patients with positive SLNB. Descriptive statistics of the clinicopathological profile by type of lymph node surgery
n (%) | n (%) | P value | ||
|---|---|---|---|---|
CLND | ||||
Overall | No | Yes | ||
N=280 | N=81 (28.9%) | N=199 (71.1%) | ||
Age (at diagnosis) | ||||
mean (SD) | 59.8 (15.8) | 62.9 (17.3) | 58.6 (15.0) | 0.017 (0.049*) |
median (IQR) | 61 (48–72) | 66 (50–79) | 60 (46–71) | |
Sex | ||||
Male | 186 (66.4%) | 51 (63.0%) | 135 (67.8%) | 0.520 |
Female | 94 (33.6%) | 30 (37.0%) | 64 (32.2%) | |
pN-value | ||||
1 | 170 (60.7%) | 52 (64.2%) | 118 (59.3%) | 0.029 |
2 | 81 (28.9%) | 26 (32.1%) | 55 (27.6%) | |
3 | 28 (10.0%) | 2 (2.5%) | 26 (13.1%) | |
Missing | 1 (0.4%) | (1.2%) | 0 (0.0%) | |
Breslow-thickness | ||||
≤ 1 | 26 (9.3%) | 7 (8.6%) | 19 (9.6%) | 0.757 |
> 1–2 | 73 (26.1%) | 24 (29.6%) | 49 (24.6%) | |
> 2–4 | 94 (33.6%) | 24 (29.6%) | 70 (35.2%) | |
> 4.00 | 73 (26.1%) | 22 (27.2%) | 51 (25.6%) | |
Missing | 14 (5.0%) | 4 (4.9%) | 10 (5.0%) | |
Ulceration | ||||
Present | 125 (44.6%) | 35 (43.2%) | 90 (45.2%) | 0.869 |
Absent | 145 (51.8%) | 43 (53.1%) | 102 (51.3%) | |
Missing | 10 (3.6%) | 3 (3.7%) | 7 (3.5%) | |
Mitotic count | ||||
0 | 10 (3.6%) | 4 (4.9%) | 6 (3.0%) | 0.675 |
1–6 | 161 (57.5%) | 45 (55.6%) | 116 (58.3%) | |
> 6 | 86 (30.7%) | 25 (30.9%) | 61 (30.7%) | |
Missing | 23 (8.2%) | 7 (8.6%) | 16 (8.0%) | |
Median (Q1-Q3) | 5 (2–9) | 4 (2.25–8.75) | 5 (2.00–8.50) | 0.936 |
TILs | ||||
Present | 179 (63.9%) | 49 (60.5%) | 130 (65.3%) | 0.994 |
Absent | 74 (26.4%) | 21 (25.9%) | 53 (26.6%) | |
Missing | 27 (9.6%) | 11 (13.6%) | 16 (8.0%) | |
Growth pattern | ||||
Vertical | 221 (78.9%) | 62 (76.6%) | 159 (79.9%) | 1 |
Radial | 3 (1.1%) | 1 (1.2%) | 2 (1.0%) | |
Missing | 56 (20.0%) | 18 (22.2) | 38 (19.1%) | |
Anatomical site | ||||
Upper limbs | 28 (10.0%) | 5 (6.2%) | 23 (11.6%) | 0.355 |
Lower limbs | 45 (16.1%) | 15 (18.5%) | 30 (15.1%) | |
Hands/feet | 25 (8.9%) | 6 (7.4%) | 19 (9.6%) | |
Head | 21 (7.5%) | 9 (11.1%) | 12 (6.0%) | |
Trunk | 155 (55.4%) | 43 (53.1%) | 112 (56.3%) | |
Missing | 6 (2.1%) | 3 (3.7%) | 3 (1.5%) | |
Histotype | ||||
Superficial spreading | 135 (48.2%) | 32 (39.5%) | 103 (51.8%) | 0.028 (ssp vs nod: 1.000) |
Nodular melanoma | 95 (33.9%) | 26 (32.1%) | 69 (34.7%) | |
Other | 12 (4.3%) | 5 (6.2%) | 7 (3.5%) | |
Not specified | 38 (13.6%) | 18 (22.2%) | 20 (10.0%) | |
Therapy | ||||
Chemotherapy | 111 (39.6%) | 24 (29.6%) | 87 (43.7%) | 0.040 |
Checkpoint inhibitors | 75 (26.8%) | 17 (21.0%) | 58 (29.1%) | 0.212 |
Target therapy | 62 (22.1%) | 21 (25.9%) | 41 (20.6%) | 0.416 |
Radiotherapy | 32 (11.4%) | 4 (4.9%) | 28 (14.1%) | 0.037 |